MJN Neuroservices
MJN Neuroservices develops AI-powered wearable earpieces (mjn-SERAS / EPISERAS®) that monitor brain activity through the ear canal to predict epileptic seizure risk in real time, serving patients with drug-resistant epilepsy in Spain, the UK, and the Netherlands with planned pan-European expansion via Neuraxpharm.
- Company typePrivate
- Founded2015
- HeadquartersGirona, Spain
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What MJN Neuroservices does
MJN Neuroservices (legal: MJN NEUROSERVEIS, S.L.) is a privately-held Spanish medical device company founded in 2014/2015 and headquartered in Blanes, Girona. The company designs and manufactures AI-powered wearable earpieces that monitor brain electrical activity through the ear canal (ear-EEG) to predict epileptic seizure risk in real time. Its flagship product, mjn-SERAS, is a custom-fitted ear-mold device with embedded sensors paired with a mobile app, certified as a CE Class IIa medical device under EU MDR 2017/745 and UKCA Class IIa, with clinically validated performance of 96% sensitivity and 94% specificity. The technology is also being extended into Alzheimer's early detection through the DREAMER project (CDTI Misiones-funded) and the RETECH-backed mjn-BRiAN clinical decision support tool, with the outpatient mjn-VISOR EEG Holter system rounding out a broader neurological wearable portfolio.
The company operates a three-pronged revenue model: direct-to-consumer hardware sales of mjn-SERAS (priced in Euros with bundled mobile app), recurring annual maintenance subscriptions (Bronze / Silver / Gold tiers offering 2, 5, or unlimited algorithm re-personalizations per year), and licensing of the EPISERAS® brand to Neuraxpharm for pan-European commercial distribution starting H2 2026. Sales are currently executed through the mjn.cat e-commerce site in Spain, with availability extended to the UK and Netherlands via direct channels, while customers must complete an online eligibility test and visit an audioprotesist center for ear-mold customization. The go-to-market combines this D2C motion in Spain with enterprise channel-partner motion via Neuraxpharm across Europe, supported by clinical validation partnerships with Oxford University Hospital, Diakonie Kork, and Clínica Universidad de Navarra under the EIT Health consortium grant.
MJN is sustained by a portfolio of non-dilutive grants — including Horizon 2020 SME Instrument Phase 2 (€850K), CDTI Misiones (€1.44M+), and EIT Health Start-up Amplifier (€2.76M) — totaling well over €5M, alongside ENISA and Ship2B/Capital Cell participation. The 8-person team is led by CEO and co-founder David Blánquez, with a chief medical officer (Dra. Gloria Durán), CTO (Xavier Raurich), and an advisory board providing AI (PhD Beatriz López), neurology (Dr. Luismi Aras of Apoyo Dravet), and healthcare network expertise (Adrián Trejo of Neurociencias Corachan). The company has accumulated over 20 industry and innovation awards, including the WSA Global Champion for best digital health project in the world, and holds the Segell PYME Innovadora designation from the Spanish Ministry of Science, Innovation and Universities.
MJN Neuroservices firmographics
Firmographics- Name
- MJN Neuroservices
- Legal name
- MJN NEUROSERVEIS, S.L.
- Website
- https://mjn.cat
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MJN Neuroservices develops AI-powered wearable earpieces (mjn-SERAS / EPISERAS®) that monitor brain activity through the ear canal to predict epileptic seizure risk in real time, serving patients with drug-resistant epilepsy in Spain, the UK, and the Netherlands with planned pan-European expansion via Neuraxpharm.
- Ownership category
- akta.pro rank
MJN Neuroservices industry classification
Industry- Product category
- Wearable Neurological Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where MJN Neuroservices is headquartered
LocationHeadquarters
- HQ city
- Girona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
MJN Neuroservices business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- mjn-SERAS Medical Device Sales: One-time sale of the mjn-SERAS wearable medical device (earpiece + mobile app). The product is sold as a combined unit — the earpiece cannot be purchased separately from the companion mobile app. Price is set on the website in Euros (VAT and delivery costs included). Currently sold in Spain with European expansion planned.
- Annual Maintenance Plans (Bronze / Silver / Gold): Recurring annual subscription plans (Bronze, Silver, Gold) that provide algorithm re-personalization (2, 5, or unlimited times per year respectively), access to seizure reports, and software updates. First 1–2 years of maintenance included with device purchase. Without a maintenance plan, device reliability degrades over time.
- EPISERAS® Licensing to Neuraxpharm: Partnership with Neuraxpharm for European commercialization of EPISERAS® (the same core technology branded differently). Neuraxpharm is a European pharmaceutical company specializing in CNS disorders, providing distribution and market access across Europe.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | mjn-SERAS Device (one-time purchase, bundled with mobile app) |
| Subscription | Annual | Bronze Plan — 2x algorithm re-personalizations per year |
| Subscription | Annual | Silver Plan — 5x algorithm re-personalizations per year |
| Subscription | Annual | Gold Plan — Unlimited algorithm re-personalizations per year |
| Freemium | Pay-as-you-go | Social-SERAS App (free) |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels9 records
MJN Neuroservices product offering
Product offeringCore offering
MJN Neuroservices designs, manufactures, and commercializes AI-powered wearable medical devices for neurological disease management. Its flagship mjn-SERAS product is a CE-certified Class IIa custom-fitted earpiece that continuously monitors brain electrical activity through ear canal sensors and uses personalized AI algorithms to predict epileptic seizure risk minutes in advance, alerting patients via a companion mobile app. The company also develops mjn-VISOR for outpatient EEG monitoring and DREAMER for early Alzheimer's detection using AI and EEG.
Product overview
MJN Neuroservices develops a portfolio of AI-powered wearable medical devices for neurological disease management. The core product is mjn-SERAS, a CE-certified Class IIa wearable earpiece that continuously monitors brain electrical activity via ear canal sensors and uses AI algorithms to predict seizure risk, paired with a mobile app. Under the EPISERAS® brand (distributed via Neuraxpharm partnership), the same technology reaches European markets. Supporting products include mjn-VISOR for outpatient EEG monitoring and DREAMER for Alzheimer's early detection using AI and non-invasive EEG recordings. The Social-SERAS companion app enables daily seizure tracking and data sharing with healthcare providers.
Differentiator
Problem solved
Functional benefit
Brands
- mjn-SERAS: A support system for people with epilepsy - a wearable earpiece that monitors brain activity and predicts seizure risk using AI algorithms
- DREAMER
- mjn-VISOR
- EPISERAS
Products and services
- mjn-SERAS Wearable medical device earpiece that continuously monitors brain electrical activity through ear canal sensors and uses AI algorithms to predict and alert users to epileptic seizure risk in real-time. Sold as a combined unit with a companion mobile app. CE Class IIa certified medical device for patients with drug-resistant epilepsy.
- EPISERAS® Commercial digital health solution branded for distribution by Neuraxpharm. AI-powered wearable earpiece device for early detection of epileptic seizures. CE Class IIa and UKCA Class IIa certified. Target: patients with drug-resistant epilepsy across Europe.
- mjn-VISOR System for monitoring brain activity in an outpatient/ambulatory setting. EEG Holter register device using portable, discrete, and non-invasive wearables allowing patients to perform daily activities while recording brain electrical activity comfortably.
- DREAMER Project for early detection and monitoring of Alzheimer's disease using AI techniques and non-invasive EEG recordings. Development of a portable, non-invasive wearable device with cognitive markers for early diagnosis of Alzheimer's in pre-clinical phase, targeting 12–18 months earlier than current diagnostic standards.
- Social-SERAS App Free companion mobile application for daily epilepsy management. Allows users to track seizure records and daily activities organized in calendar format. Enables sharing of data with neurologists for quick visualization of epilepsy evolution and patterns. Includes community features.
- Annual Maintenance Plans (Bronze / Silver / Gold) Recurring annual subscription plans providing algorithm re-personalization (Bronze: 2x/year, Silver: 5x/year, Gold: unlimited per year), access to seizure reports, and software updates. Required for maintaining device prediction accuracy over time.
Quantifiable outcome
- 96% sensitivity and 94% specificity in seizure prediction
- +3 more outcomes
Companies that use MJN Neuroservices
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
MJN Neuroservices technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
MJN Neuroservices partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered flagship, core and minor.
- NeuraxpharmflagshipStrategic partnership for pan-European commercialization of EPISERAS® — the AI-powered seizure detection wearable developed by mjn-neuro. Neuraxpharm, a leading European CNS pharmaceutical company, will distribute EPISERAS® across Europe starting H2 2026. The partnership leverages Neuraxpharm's established neurology prescribing networks and pharmaceutical sales infrastructure. MJN-neuro initiated collaboration with Neuraxpharm in 2022.
- ACCIÓ (Generalitat de Catalunya)coreCatalan government innovation agency providing grant support for mjn-BRiAN project (AI-driven clinical decision support tool for Alzheimer's detection) and 2020 innovation voucher program for Alzheimer detection prototype development (Expediente ACE008/20/000316).
- ELAUSA ELECTRONICA I AUTOMATISMES S.L.minorTechnology partner in the CDTI Misiones DREAMER project for early Alzheimer's detection using AI and EEG technology.
- INSTITUTO MEDICO PRIVADO S.L.P.minorMedical institution partner in the CDTI Misiones DREAMER project contributing clinical validation for Alzheimer's early detection using AI and EEG.
- WEIRD KIN S.L.minorTechnology company partner in the CDTI Misiones DREAMER project for Alzheimer's early detection combining EEG and AI technologies.
- FEMenGIN (Udg)minorGender diversity in engineering initiative at the Polytechnic School of the University of Girona. MJN supports women engineers and participates in roundtables promoting gender diversity in technology careers.
- Oxford University Hospital NHS Foundation TrustcoreUK hospital partner within the EIT Health Start-up Amplifier Instrument consortium (Grant 220445) focused on 'Improving Quality of Life for People with Epilepsy in Europe'. Contributing clinical validation expertise and UK market access for mjn-SERAS.
- Clínica Universidad de NavarracoreSpanish hospital partner in the EIT Health consortium. Collaborating on clinical validation of mjn-SERAS and European market preparation for the device.
- Diakonie KorkcoreGerman healthcare institution partner in the EIT Health consortium contributing to European clinical validation and market access for mjn-SERAS in Germany.
- Medical Valley (Germany)coreGerman medical technology cluster partner in the EIT Health consortium, supporting MJN's market entry and ecosystem integration in Germany.
- Biocat (Catalonia)coreCatalan biocluster supporting the EIT Health consortium and MJN's ecosystem integration in the Catalonia health innovation network.
- IESE Business SchoolcoreSpanish business school partner in the EIT Health consortium providing strategic business advisory, go-to-market strategy, and market expansion expertise for European scaling.
- Fundación DKV IntegraliacoreSpanish healthcare foundation partner in the EIT Health consortium supporting social impact and patient community engagement for the epilepsy device.
- Hospital Ruber Internacional de MadridcoreCollaborating on the EPISOFT clinical validation study expanding from 30 to 50 patients. Contributed to algorithm validation for mjn-SERAS.
- eXiT Research Group (Universitat de Girona)coreResearch collaboration under the Retos Colaboración program (RTC-2017-6701-1, FEDER-funded) for developing predictive methods from biomedical data. The eXiT group has extensive experience creating predictive models from biomedical data for the mjn-SERAS algorithm.
- ALCE (Apoyo Dravet)minorSpanish patient association for Dravet syndrome and related epilepsies. Collaboration on the Horizon 2020 Big Data project and webinar participation for patient education and community engagement.
- Ship2B (Impact Forum)minorExhibitor at the VII S2B Impact Forum (Impact Expo), Spain's largest impact economy event with 3,000+ attendees, for visibility and community building in the impact/startup ecosystem.
- Corachan Neuroscience DirectorateminorAdvisory board member Adrián Trejo serves as Director of Neurociencias Corachan, providing clinical and healthcare network connections in the Barcelona healthcare ecosystem.
- FEDE (Federación Española de Epilepsia)minorSpanish Epilepsy Federation. MJN participated in the III Research Fair on Epilepsy organized by FEDE to present mjn-SERAS to the epilepsy patient and professional community.
- D'Genes (Asociación de Enfermedades Raras)minorRare disease association organizing the II National Epilepsy Congress where mjn-neuro presented the mjn-SERAS project to families and healthcare professionals.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
MJN Neuroservices competitors and assessment
Company assessmentDirect peers
- Empatica: Empatica's Embrace / EpiMonitor is the most direct competitor to mjn-SERAS — a wearable for seizure detection, FDA-cleared, sold to the same drug-resistant epilepsy patient population. Both are AI-driven wearables designed for ambulatory seizure monitoring outside the clinic.
- Brain Sentinel: Brain Sentinel developed the SPEAC system, an FDA-cleared surface-EMG based seizure detection wearable. Comparable business model and patient population, though different signal modality (sEMG vs. EEG).
Emerging players
- Epitel: Epitel makes PEAT, a small wearable EEG sensor for seizure monitoring, closely aligned with MJN's EEG-based approach. Targets similar neurology use cases but with a different form factor (behind-the-ear patch vs. in-ear).
- iMediSync: iMediSync develops EEG-based screening/diagnostic tools for early detection of neurological conditions (including Alzheimer's and dementia). Highly relevant to MJN's DREAMER project, which applies a similar early-detection thesis via EEG.
- Zeto: Zeto offers a wireless, easy-to-wear EEG headset for ambulatory brain monitoring. Comparable in that it brings EEG out of the clinical lab into the patient's daily environment — overlapping with MJN's mjn-VISOR strategy.
Broad incumbents
- Ceribell: Ceribell is a broader neurodiagnostic incumbent with point-of-care EEG and AI-based brain monitoring. Not a direct seizure-prediction wearable, but operates in the same neurology and EEG-monitoring category and competes for hospital neuro-monitoring budgets.
- Compumedics: Compumedics manufactures EEG and sleep-diagnostic systems used in hospitals and research. Operates in the same neuro-monitoring space and could plausibly enter the ambulatory seizure-prediction wearable category where MJN plays.
- Brain Products: Brain Products is a leading European EEG hardware and software maker, based in Germany. Same category (EEG instrumentation) and overlapping European clinical/research customer base, though focused on research-grade systems rather than wearables.
- Nihon Kohden: Nihon Kohden is a large established player in neurodiagnostic instrumentation (EEG, EMG, ICU monitoring). A broad incumbent whose portfolio overlaps with MJN's clinical/EEG ambitions — relevant as a much larger potential competitor or acquisition target.
Regional players
- Bitbrain: Bitbrain is a Spanish/European EEG wearable platform for research and applied neuroscience. Closely comparable in form factor (wearable EEG) and home geography (Iberia/Europe), even though its focus is research/B2B rather than patient-direct seizure prediction.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MJN Neuroservices social profiles
Digital presenceMJN Neuroservices compliance and trust
Trust signalCompliance5 records
MJN Neuroservices financial estimates
Financial estimateRevenue estimate
Valuation estimate
MJN Neuroservices leadership team
Management profileNumber of profiles
Profiles9 records
MJN Neuroservices funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MJN Neuroservices M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MJN Neuroservices
What does MJN Neuroservices do?
MJN Neuroservices designs, manufactures, and commercializes AI-powered wearable medical devices for neurological disease management. Its flagship mjn-SERAS product is a CE-certified Class IIa custom-fitted earpiece that continuously monitors brain electrical activity through ear canal sensors and uses personalized AI algorithms to predict epileptic seizure risk minutes in advance, alerting patients via a companion mobile app. The company also develops mjn-VISOR for outpatient EEG monitoring and DREAMER for early Alzheimer's detection using AI and EEG.
Is MJN Neuroservices a public or private company?
MJN Neuroservices is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MJN Neuroservices founded?
MJN Neuroservices was founded in 2015. It employs 1 to 10 people.
Where is MJN Neuroservices based?
MJN Neuroservices is headquartered in Girona, Spain, in the Europe region.
How does MJN Neuroservices make money?
Three revenue lines are on record. mjn-SERAS Medical Device Sales are the primary driver. The others are annual Maintenance Plans (Bronze / Silver / Gold) and EPISERAS® Licensing to Neuraxpharm.
Who are MJN Neuroservices's main competitors?
Direct peers on record are Empatica and Brain Sentinel. Emerging players are Epitel, iMediSync and Zeto. Broad incumbents are Ceribell, Compumedics, Brain Products and Nihon Kohden. Bitbrain is listed as a regional player.
Does MJN Neuroservices have an API?
No public API is recorded for MJN Neuroservices.
What industry is MJN Neuroservices in?
MJN Neuroservices's product category is Wearable Neurological Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.